- Home
- DSGX vs BPMC Comparison
DSGX vs BPMC Comparison
Compare DSGX & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGX
- BPMC
- Stock Information
- Founded
- DSGX 1981
- BPMC 2008
- Country
- DSGX Canada
- BPMC United States
- Employees
- DSGX N/A
- BPMC N/A
- Industry
- DSGX Computer Software: Prepackaged Software
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- DSGX Technology
- BPMC Health Care
- Exchange
- DSGX Nasdaq
- BPMC Nasdaq
- Market Cap
- DSGX 8.8B
- BPMC 8.3B
- IPO Year
- DSGX 1999
- BPMC 2015
- Fundamental
- Price
- DSGX $101.87
- BPMC $129.32
- Analyst Decision
- DSGX Buy
- BPMC Buy
- Analyst Count
- DSGX 7
- BPMC 20
- Target Price
- DSGX $125.14
- BPMC $127.82
- AVG Volume (30 Days)
- DSGX 453.2K
- BPMC 3.3M
- Earning Date
- DSGX 09-03-2025
- BPMC 07-31-2025
- Dividend Yield
- DSGX N/A
- BPMC N/A
- EPS Growth
- DSGX 17.84
- BPMC N/A
- EPS
- DSGX 1.65
- BPMC N/A
- Revenue
- DSGX $668,391,000.00
- BPMC $562,121,000.00
- Revenue This Year
- DSGX $11.87
- BPMC $44.46
- Revenue Next Year
- DSGX $13.36
- BPMC $32.78
- P/E Ratio
- DSGX $61.29
- BPMC N/A
- Revenue Growth
- DSGX 13.74
- BPMC 99.19
- 52 Week Low
- DSGX $90.61
- BPMC $73.04
- 52 Week High
- DSGX $124.31
- BPMC $129.49
- Technical
- Relative Strength Index (RSI)
- DSGX 46.22
- BPMC 76.79
- Support Level
- DSGX $101.06
- BPMC $128.06
- Resistance Level
- DSGX $104.41
- BPMC $129.49
- Average True Range (ATR)
- DSGX 2.38
- BPMC 0.27
- MACD
- DSGX 0.49
- BPMC -0.97
- Stochastic Oscillator
- DSGX 54.96
- BPMC 87.41
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.